The eLitMed.hu medical portal uses computer cookies for convenient operation. Detailed information can be found in the Cookie-policy.
Specialities
Endocrinology
Hypertension and nephrology
OCTOBER 30, 2023
[Is hypertension different for women and men?]
[Hypertension is a risk factor for cardiovascular diseases in both men and women. Lifelong studies have proven that women suffer from high blood pressure in old age more often than men and this is often associated with obesity, dyslipidemia, and diabetes. All of this can most likely be related to menopause, when one of the most important female sex hormones, estrogen’s vascular protective and anti-inflammatory effect ceases. It has also been proven that pregnancy is also a test for the vascular system. Pathological abnormalities during pregnancy increase the cardiovascular risk later on. Differences can be detected in the regulation of blood pressure, as a result of the autonomic nervous system and hormonal effects. Differences can also be discovered in relation to common cardiovascular diseases. Although the recommendations do not currently differentiate, the effectiveness of the therapies and the frequency of side effects may also differ. Recent researches conclude that women’s cardiovascular risk is manifested in lower blood pressure values than men’s. It is possible that we should modify the threshold and target values of women’s blood pressure in order to decrease the proven cardiovascular risk of high blood pressure in women through well-planned therapy.]
Hypertension and nephrology
OCTOBER 30, 2023
[Double endothelin receptor inhibitors]
[A common problem in the hypertension care is the treatment of cases that react difficultly to treatment, including resistant hypertension. The structure of the treatment is particularly challenging. Intensive research is underway in the field of developing new drugs that can be used in the treatment of resistant hypertension, one possibility being dual endothelin receptor inhibitors. In my article, based on the results of the recently published PRECISION study, I present the possible use of the drug group in this area.]
Clinical Neuroscience
SEPTEMBER 30, 2023
[Sumatriptan-naproxen sodium fix-dose combination for acute migraine treatment, a review]
[Migraine as a common primary headache disorder has a significant negative effect on quality of life of the patients. Its pharmacotreatment includes acute and preventative therapies. Based on the shared therapeutic guideline of the European Headache Federation and the European Academy of Neurology for acute migraine treatment a combination of triptans and non-steroidal anti-inflammatory drugs is recommended for acute migraine treatment in triptan-nonresponders. In this short review we summarized the results of the randomized controlled clinical trials evaluating the effectiveness and safety of sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination. It was revealed that the fix-dose combination was better than placebo for the primary outcomes of exemption of pain and headache relief at 2 hours. Furthermore the combination showed beneficial effect on accompanying symptoms of migraine attack (i.e. nausea, photo- and phonophobia). Adverse events were mild or moderate in severity and rarely led to withdrawal of the drug.
It can be concluded that sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination is effective, safe and well-tolerated in the acute treatment of migraine. ]
Clinical Neuroscience
SEPTEMBER 30, 2023
Efficacy of intravenous alpha lipoic acid in the treatment of neuropatic pain due to carpal tunnel syndrome
In this study, we analyzed the effect of oral and oral + intravenous Alpha-lipoic acid (ALA) treatment on pain level and physical examination findings in patients diagnosed with carpal tunnel syndrome (CTS). A total of 115 patients patricipated in the study. 40 patients were treated with oral ALA after iv. ALA the¬rapy, 35 patients received only oral ALA treatment and 40 patients did not receive any medication.
Clinical Neuroscience
SEPTEMBER 30, 2023
Neurobehavioral impairments in ciprofloxacin- treated osteoarthritic adult rats
Ciprofloxacin (CIP) is a broad-spectrum antibiotic widely used in clinical practice to treat musculoskeletal infections. Fluoroquinolone-induced neurotoxic adverse events have been reported in a few case reports, all the preclinical studies on its neuropsychiatric side effects involved only healthy animals. This study firstly investigated the behavioral effects of CIP in an osteoarthritis rat model with joint destruction and pain.
Clinical Neuroscience
SEPTEMBER 30, 2023
Prognostic value of indoleamine 2, 3-dioxygenase-1 expression in glial tumors
Gliomas are the most common primary malignant central nervous system tumors in adults, exhibiting a poor prognosis. Indoleamine 2, 3-dioxygenase-1 has important functions in cancer immunotherapy due to its role in escaping cancer cells from the immune system. In this study we purposed to evaluate the correlation between IDO-1 expression and clinicopathological parameters in gliomas, and whether IDO-1 can be a prognostic marker.
1.
Clinical Neuroscience
[Headache registry in Szeged: Experiences regarding to migraine patients]
21. MAY
2.
Clinical Neuroscience
[The new target population of stroke awareness campaign: Kindergarten students ]
21. MAY
3.
Clinical Neuroscience
Is there any difference in mortality rates of atrial fibrillation detected before or after ischemic stroke?
27. NOV
4.
Clinical Neuroscience
Factors influencing the level of stigma in Parkinson’s disease in western Turkey
27. SEP
5.
Clinical Neuroscience
[The effects of demographic and clinical factors on the severity of poststroke aphasia]
18. JUL
1.
2.
Clinical Oncology
[Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up]
29. AUG
3.
Clinical Oncology
[Pharmacovigilance landscape – Lessons from the past and opportunities for future]
29. AUG
4.
5.